国家科技奖|“药中找药”为创新药物研发奠定科学基础

2018-02-28 方碧陶 中国中医药报

日前,《中药和天然药物的三萜及其皂苷成分研究与应用》项目获得2017年国家科学技术进步奖二等奖。该项目明确了60余种中药和天然药物的物质基础,攻克了分离鉴定强水溶性三萜皂苷这一难点。

日前,《中药和天然药物的三萜及其皂苷成分研究与应用》项目获得2017年国家科学技术进步奖二等奖。该项目明确了60余种中药和天然药物的物质基础,攻克了分离鉴定强水溶性三萜皂苷这一难点。

一株开着白色小花的地乌,采摘,洗净,根茎切段,便成中医治疗风湿疼痛、跌打损伤的良药。在治疗疾病时发挥关键作用的,是地乌中所含的三萜及其皂苷类成分。

“三萜及其皂苷类成分是许多中药和天然药物的药效物质基础。”刚带领团队以中药和天然药物的三萜及其皂苷成分研究与应用项目获得国家科学技术进步奖二等奖的暨南大学教授叶文才表示,有近一半的中药和天然药物中含有三萜及其皂苷类成分。如果不能明确该类成分的化学组成、药理活性和作用机制等,将会影响中药和天然药物的质量标准建立和相关产品的研发。

通过对白头翁、地乌、岗梅等60余种中药和天然药物中的三萜及其皂苷活性成分的系统研究,叶文才团队取得了创新性研究成果,为中药和天然药物物质基础的阐明、质量标准建立、创新药物研发及名优中成药的二次开发提供了有力的科技支撑。

攻克难题成果显

“含有三萜及其皂苷类成分的中药和天然药物太多,有很多化学成分仍是没有研究过的。”叶文才表示,三萜及其皂苷类成分种类繁多、结构复杂。虽然目前对其中的人参皂苷和三七皂苷的研究已取得了不少成果,还研发出了人参皂苷Rg1等产品,但这对于庞大的三萜及其皂苷类家族而言只如同沧海一粟。

为了明确三萜及其皂苷类的化学结构、药理活性和作用机制,叶文才和团队选取了包括白头翁、岗梅、地乌等在内的60余种中药和天然药物进行研究。

药材经过水煎、酒精提取等步骤后,通过现代分离技术,将其中的三萜皂苷类成分和其他化学成分一个个分离出来。再通过光谱鉴定方法等手段,确定各成分的化学结构,并进行生物活性试验,最终确定其治疗等用途。

在分离提取药用植物岗梅皂苷时,叶文才团队被这类三萜皂苷的强水溶性扼住了脚步。因岗梅中的三萜皂苷分子中含有磺酸基和糖醛酸基团,与植物中的无机离子形成盐,使这类三萜皂苷的水溶性显着增强,导致该类成分分离纯化和结构鉴定的难度增大。叶文才团队反复实验,终于摸索出了这类三萜皂苷成分的最佳分离和结构测试条件。“我们得出的经验,也为今后其他中药和天然药物的研究提供了借鉴和参考。”叶文才说。

功夫不负有心人,叶文才团队研究成果显着,共分离鉴定了1100余个三萜及其皂苷类成分,其中330余个为新化合物,2个为新骨架结构,不仅明确了上述中药和天然药物的物质基础,丰富了该类天然产物的结构类型,还为质量标准的建立或提升、创新药物研发提供了化学对照品和样品库。除获得国家科学技术进步奖二等奖之外,研究项目还入选2017年度中国十大医学进展。

建立质控保安全

参芪扶正注射液是一种临床常用的对肺癌胃癌等有辅助治疗功效的静脉注射液,但质量检测标准有待提升和完善。叶文才团队对参芪扶正注射液中的化学成分和指纹图谱进行了研究,并与生产企业一起完善了该注射液的质量控制体系,有效地提高了产品质量控制的科学性,使该注射液产品的均一性和安全性有了进一步的保障,取得了明显的社会和经济效益。

除此之外,2015版的《中国药典》也收录了基于该项目研究成果建立的白头翁含量测定标准,该质控标准专属性强、灵敏度高,为白头翁药材、饮片和相关产品的质量控制提供了有效的方法。

“早期没有明确中药和天然药物的活性成分时,中药和天然药物质量标准的制定受到了很大的影响。”叶文才表示,不管是中药还是西药,如果没有明确其中的化学成分,就无法通过对照物来建立质量标准。而只有建立完善的质量标准,药品质量和安全性才能不断提高。

药中取药促研发

抗疟良药青蒿素从中药青蒿中提取,是创新药物研发的典范。三萜及其皂苷类成分如青蒿素一样,存在于中药和天然药物中,通过科技手段将其提取分离出来,并从中研发出一些创新药物。叶文才称之为“在药中找药”。

地乌总皂苷是国家五类中药新药地乌风湿安胶囊的原料,存在于草药地乌之中。但由于在研发初期对地乌中皂苷的种类和化学结构并没有完全明确,采用的含量测定方法也无法正确反映药物中皂苷成分的含量,叶文才团队将地乌中的皂苷成分一个一个地分离出来,并通过现代光谱方法鉴定结构,然后选取含量最高的皂苷成分作为对照品,通过“一测多评”的方法,成功地测定了地乌总皂苷的含量。

另外,该团队还对地乌总皂苷治疗类风湿性关节炎的作用机制进行了深入的研究,推进了地乌风湿安胶囊的新药研发进程。

“我们这个获奖项目,一大半是基础性研究工作,但研究成果完全可以与应用对接。”叶文才团队在项目研究中发现了多个新药先导物,并阐述了它们的作用机制,为创新药物研发奠定了科学基础。叶文才表示,团队除了进行三萜及其皂苷的研究,还关注岭南地区中草药的活性成分研究,认为该地区的中草药品种比较独特,但人们以前研究和关注较少,岭南地区中草药将为我国中医药发展和创新药物研发作出更大的贡献。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-03-02 lqvr
  6. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1721460, encodeId=99301e21460e8, content=<a href='/topic/show?id=c7c5e4947cb' target=_blank style='color:#2F92EE;'>#科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74947, encryptionId=c7c5e4947cb, topicName=科技奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=423733003907, createdName=w363522460, createdTime=Thu Apr 26 09:52:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923604, encodeId=f33f192360414, content=<a href='/topic/show?id=f9f25864447' target=_blank style='color:#2F92EE;'>#新药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58644, encryptionId=f9f25864447, topicName=新药物)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 20 13:52:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981178, encodeId=cc1a19811e859, content=<a href='/topic/show?id=773f4093202' target=_blank style='color:#2F92EE;'>#国家科技奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40932, encryptionId=773f4093202, topicName=国家科技奖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Nov 08 14:52:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285536, encodeId=12d312855363e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300122, encodeId=77ea13001224b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301450, encodeId=6e0a130145056, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Mar 02 10:52:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291780, encodeId=67cd291e804e, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 28 20:48:14 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291760, encodeId=cc4f291e60f2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 20:06:14 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0